Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.
KalVista Pharmaceuticals, Inc. (KALV) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. The company's mission is to bring innovative treatments to patients suffering from a range of diseases, with a strong focus on hereditary angioedema (HAE) and diabetic macular edema (DME).
KalVista's core business revolves around developing small molecule plasma kallikrein inhibitors. Their product portfolio includes:
- Hereditary Angioedema (HAE) inhibitors: These inhibitors are designed to prevent and treat the debilitating attacks associated with HAE, a disorder characterized by severe swelling in various body parts.
- Diabetic Macular Edema (DME) inhibitors: These inhibitors target plasma kallikrein, which is implicated in the retinal vascular permeability that leads to DME, a common complication of diabetes that can cause vision loss.
The company operates primarily in the United States and has made significant strides in its research and development efforts. Recent achievements include successful clinical trials, strategic partnerships, and securing funding to advance their pipeline projects.
KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments. The company prioritizes transparency and regularly updates stakeholders on its progress through press releases and public disclosures.
Investors looking to keep abreast of the latest developments and financial performance of KalVista Pharmaceuticals can find comprehensive updates and reports on their official website and through stock market platforms like StockTitan.
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. announces the pricing of its underwritten public offering, expecting gross proceeds of $160.1 million. The offering includes common stock and pre-funded warrants, with an option for additional shares. The pre-funded warrants are immediately exercisable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
News
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) announces a public offering of common stock and pre-funded warrants to certain investors. The company plans to use the proceeds for the clinical development of its product candidate sebetralstat and other activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announces positive results from the phase 3 KONFIDENT clinical trial for sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). The trial showed statistically and clinically significant efficacy, with a favorable safety profile. Sebetralstat achieved symptom relief faster than placebo, with no serious adverse events. The Company plans to submit a new drug application to the U.S. FDA in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.42%
Tags
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (KALV) recently granted four newly-hired employees inducement options to purchase an aggregate of 42,000 shares of KalVista common stock. The options have an exercise price of $15.74 per share and vest over a four-year period. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announces the publication of data on the first report of an oral, potent, and selective FXIIa inhibitor in the peer-reviewed scientific journal, Frontiers in Pharmacology. The article describes the pharmacology of a representative compound from KalVista’s portfolio of oral Factor XII inhibitors, including potent, selective inhibition of both FXII zymogen and FXIIa, blockage of KKS-mediated edema in preclinical HAE models in vivo, and high oral availability in multiple species. This demonstrates KalVista's scientific leadership in medicinal chemistry and KKS biology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) completes the targeted number of attacks in the Phase 3 KONFIDENT Clinical Trial for sebetralstat, with data readout expected in early 2024 and NDA filing in H1 2024. The company also achieved Orphan Drug Status in Switzerland and presented real-world patient data at scientific meetings. However, the second fiscal quarter ended with no revenue, increased R&D and G&A expenses, and a net loss of $27.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) granted four newly-hired employees inducement options to purchase 43,000 shares of KalVista common stock on December 1, 2023. The options have an exercise price of $8.82 per share, one-fourth vest on the one-year anniversary, and the remainder vest in equal monthly installments over the next three years, subject to the new employee’s continued service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) presented real-world data on anxiety associated with the use of injectable on-demand treatments for hereditary angioedema (HAE) attacks and patient perspectives on why people living with HAE don’t often carry their on-demand treatment outside the home at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Anaheim, CA. The company aims to address the significant unmet need for HAE treatment and transform the management of the disease with the potential approval of sebetralstat for the on-demand treatment of HAE. The presentations also covered the global prevalence of normal C1-inhibitor HAE (HAE-nC1-INH) and the varied treatment approaches, highlighting the persisting non-medication health resource utilization among patients receiving long-term prophylaxis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) provided clinical trial and regulatory updates for its lead program sebetralstat, a potential oral on-demand therapy for hereditary angioedema (HAE). The largest-ever HAE clinical trial, KONFIDENT, has achieved the targeted number of on-treatment attacks required to complete the phase 3 trial. Topline data readout is expected in early 2024, remaining on track for a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the first half of 2024. The Company also expects to file for approval in the European Union and Japan later in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) will participate in investor conferences on November 14 and 16, 2023, presenting at the Stifel 2023 Healthcare Conference and Jefferies London Healthcare Conference. The presentations will be available via live webcast on the company's website, with an audio archive accessible for 30 days after the events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
FAQ
What is the current stock price of KalVista Pharmaceuticals (KALV)?
The current stock price of KalVista Pharmaceuticals (KALV) is $8.76 as of January 7, 2025.
What is the market cap of KalVista Pharmaceuticals (KALV)?
The market cap of KalVista Pharmaceuticals (KALV) is approximately 433.4M.
What does KalVista Pharmaceuticals specialize in?
KalVista Pharmaceuticals specializes in the discovery, development, and commercialization of small molecule protease inhibitors.
What diseases does KalVista target with its products?
KalVista targets hereditary angioedema (HAE) and diabetic macular edema (DME) with its products.
What is a plasma kallikrein inhibitor?
A plasma kallikrein inhibitor is a type of medication that blocks the action of plasma kallikrein, which plays a role in conditions like HAE and DME.
Where does KalVista Pharmaceuticals operate?
KalVista Pharmaceuticals operates primarily in the United States.
How can investors stay updated on KalVista's progress?
Investors can stay updated through KalVista's official website and stock market platforms like StockTitan.
Has KalVista formed any strategic partnerships?
Yes, KalVista has formed several strategic partnerships to advance its research and development efforts.
What are KalVista's recent achievements?
Recent achievements include successful clinical trials, securing funding, and strategic partnerships.
What is hereditary angioedema (HAE)?
Hereditary angioedema (HAE) is a disorder characterized by severe swelling in various parts of the body.
What is diabetic macular edema (DME)?
Diabetic macular edema (DME) is a complication of diabetes that affects the retina and can lead to vision loss.
What financial condition is KalVista in?
KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments.
KalVista Pharmaceuticals, Inc.
Nasdaq:KALV
KALV Rankings
KALV Stock Data
433.38M
43.78M
1.36%
110.29%
14.98%
Biotechnology
Pharmaceutical Preparations
United States of America
CAMBRIDGE